

Linda B. Piller, MD, MPH
Linda.B.Piller@uth.tmc.edu (wk)

EDUCATION/MEDICAL TRAINING

1986 – Medical Degree (MD)

The University of Texas Health Science Center-Houston, Medical School
Texas Medical License #H2691 – 1986

1982 – Pre-medical course requisites

Houston Baptist University/Houston Community College System - Houston, Texas

1979 – Master of Public Health (MPH)

The University of Texas Health Science Center-Houston, School of Public Health
Health Services Organization

1975 – Bachelor of Science in Education – *summa cum laude*

The University of Houston – Houston, Texas *Major: Education Minor: Psychology*

EXPERIENCE

University of Texas Health Science Center at Houston, School of Public Health

Assistant Professor

Division of Epidemiology and Disease Control

Division of Biostatistics (Secondary Appointment)

1995 - Present

2001 - Present

As the Curriculum Coordinator, Chair of the Epidemiology Curriculum Committee, and Division representative to the school-wide Academic Council for Epidemiology and Disease Prevention, I direct the Division in the curriculum development of Epidemiology and Disease Prevention courses. I teach two annual courses: The Natural History of Disease and Pathology and Public Health. In addition to my administrative and teaching duties, I serve as an advisor and member of student advisory committees for graduate physicians and doctoral students in Public Health. In the Texas (Houston) Medical Center research community I serve on two committees for the University of Texas Health Science Center institutions: The Committee for the Protection of Human Subjects (CPHS/IRB), and the Institutional Biosafety Committee.

University of Texas Health Science Center at Houston, School of Public Health, Coordinating Center for Clinical Trials

Recently Submitted Research Applications

Medical Director; Co-Investigator (25 % effort first year, 75% thereafter)

(Barry Davis, Lemuel Moye, Principal Investigators)

Cardiovascular Cell Therapy Research Network - Data Coordinating Center

NHLBI RFA HL 006-01

Submitted November 27, 2005

Awarded November 6, 2006

(Projected) 2007 – 2012

The NHLBI-sponsored Cardiovascular Cell Therapy Research Network Coordinating Center will direct phase I and II collaborative trials of emerging cell based treatments of cardiovascular disease. As Medical Director I will receive and investigate all adverse event reports and will participate in the management of medical/safety issues that arise in the clinical sites; I will work closely with the Data Safety and Monitoring Board, the Medical Care Committee, the Steering Committee and the NHLBI Project Office. I will be

responsible for the collection and evaluation of clinical outcome and endpoint event reports and laboratory results, and will be responsible for filing IND applications on behalf of the clinical network.

Hispanic Community Health Study Coordinating Center
Co-Principal Investigator, 50% effort (Barry Davis, Principal Investigator)
NHLBI RFP HL-06-01
Submitted December 1, 2005

(Not funded)

Hispanic Community Health Study Rio Grande Field Center
Co-Investigator, 5% effort (Craig Hanis, Principal Investigator)
NHLBI RFP HC-06-02
Submitted December 1, 2005

(Not funded)

Research in Progress or Completed

Director of Clinical Trial Safety and Endpoints; Co-Investigator
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
NHLBI, DHHS contract 3 N01-HC-35130 1996-Present

As Director of Endpoints and Safety for a Phase IV cardiovascular trial (population 42,118) I was responsible for the medical oversight and management of adverse events reporting and study endpoints. This NHLBI-sponsored, 600+ site trial compared treatments for hypertension among high-risk participants and examined differences in clinical outcomes among its four arms. ALLHAT included a lipid-lowering study of the effects of pravastatin (HMG CoA reductase inhibitor) vs. routine care in a subset (10,000) of study participants. I have presented abstracts involving ALLHAT data at both the American Society of Hypertension (ASH) and the Society for Clinical Trials (SCT) national meetings and have spoken about ALLHAT at local professional meetings.

Post-ALLHAT, I have assumed the Coordinating Center leadership role in the first-ever NIH supported academic detailing project for dissemination and translation of ALLHAT findings into clinical practice nation-wide. I have participated in the identification, selection and training of ALLHAT physician/investigators for this project. The program is in its 3rd year.

Medical Officer
Cholesterol and Recurrent Events (CARE) trial
Sponsored by Bristol-Myers Squibb 1995-1996

As Events and Safety Medical Officer, I coordinated the management of CARE during the last year of this Phase IV trial (study population 4,000+ at 80 American and Canadian clinics). I provided medical review and oversight of adverse events and endpoints, and worked closely with BMS in safety reporting to the FDA. This trial was collaboratively conducted at the Brigham and Women's Hospital at Harvard University and the University of Texas Health Science Center, School of Public Health, which served as the data coordinating center.

Professional Experience

The University of Texas Health Science Center-Houston, Medical School
Resident - Clinical and Anatomic Pathology 1986-1991

Performed pathology duties in surgical, autopsy, and cyto-pathology, and in all areas of clinical pathology, including chemistry, hematology, microbiology, and immunology. Served as instructor for medical student

histology and pathology laboratory courses; lectured for Obstetrics and Gynecology teaching rounds; presented at Pathology Grand Rounds, Hematology and Oncology rounds, and Autopsy rounds.

Chief Resident – Dept. of Pathology and Laboratory Medicine 1988-1989

Supervised approximately 20 first through fifth year medical residents in Pathology and Laboratory Medicine; assigned schedules; oversaw and evaluated quality of work; performed leadership duties in surgical pathology, cytopathology, autopsy pathology, and all aspects of clinical pathology.

Kott and Associates Medical Laboratories

Associate Director and Pathologist 1991-1995

Reviewed and diagnosed surgical pathology and cytology specimens; performed frozen section biopsies with immediate reporting of diagnoses; performed fine needle aspiration biopsies with immediate reporting of diagnoses; supervised laboratory cytotechnologists and staff; consulted with client physicians; visited physician clinics and instructed physicians as to appropriate cytologic and pathologic procedures; served as Certified College of American Pathology (CAP) laboratory inspector.

Beth Yeshurun Day School, Houston, TX

Elementary Teacher 1976-1980

Elementary school teacher for grades three, five, and six

SERVICE AND PROFESSIONAL ACTIVITIES

2005 – 2008 *University of Texas Health Science Center Committee for the Protection of Human Subjects* (Institutional Review Board)-appointed member.

2004 – 2008 *University of Texas Health Science Center-Houston Institutional Biological Safety Committee*-appointed member.

2000 – Present Endpoints Consultant and Committee Member “*Stress Reduction and Cardiovascular Morbidity and Mortality in African Americans*” – NHLBI #5 R01 HL 48107

2004 – Present Endpoints Consultant and Committee Member “*Stress Reduction and Atherosclerotic CVD in Blacks*” – NHLBI #5 R01 HL51519-09

2006 - Present Member, “*Atherosclerotic Risk in Communities (ARIC)*” Heart Failure Steering Committee

2006 – Present Stakeholder and Consultant, *National Accrediting Agency for Clinical Laboratory Sciences (NAACLS)*

2005 – 2006 Working Group Member, *American Schools of Public Health (ASPH) MPH Core Competencies, Public Health Biology section*, published July, 2006

May 9, 2006 Invited speaker, “*Managing Long-Term Clinical Trials: Ethical Issues.*” *National Association of GCRC Nurse Managers*. CNE credit activity.

PUBLICATIONS

1. Einhorn, P., Davis, B., **Piller, L.**, et al. Verification of Heart Failure Events in ALLHAT. Accepted for publication October 13, 2006 by the *American Heart Journal*. In press.
2. Davis, BR, **Piller, LB**, Cutler, JA. Letter to the Editor. *Circulation*. Accepted for publication Sept. 29, 2006. In press.

3. **Piller, L.**, Ford, C., Davis, B., et al. Incidence and Predictors of Angioedema in Elderly Hypertensive Patients at High Risk for Cardiovascular Disease: A Report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *The Journal of Clinical Hypertension* 2006;8;9:649-656. CME selection for September, 2006.
4. Davis, B., **Piller, L.**, Cutler, J., et al. The Role of Diuretics in the Prevention of Heart Failure: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Circulation* 2006;113:2201-2210. Selected October 23, 2006, for American College of Physicians Journal Club; in press.
5. Papademetriou, V., **Piller, L.**, Ford, C., et al. Characteristics and Lipid Distribution of a Large, High Risk, Hypertensive Population: The Lipid-Lowering Component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *J Clin Hypertens* 2003;5:377-385.
6. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Diuretic Versus α -Blocker as First Step Antihypertensive Therapy: Final Results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Hypertension*. 2003;42:239-246.
7. **Piller, L.**, Davis, B., Cutler, J., et al. Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone. *Current Controlled Trials in Cardiovascular Medicine* 2002, 3:10.
8. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002; 288:2981-2997
9. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). *JAMA* 2002; 288:2998-3007
- 10.. Cushman, W., Ford, C., Cutler, J., Margolis, K., Davis, B., Grimm, R., Black, H., Hamilton, B., Holland, J., Nwachuku, C., Papademetriou, V., Probstsfield, J., Wright, J., Alderman, MI, Weiss, R., **Piller, L.** Bettencourt, J., Walsh, S. Success and Predictors of Blood Pressure Control in Diverse North American Settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *The Journal of Clinical Hypertension* 2002;4(6):1-12).
11. Pressel, S., Davis, B., Wright, J., Geraci, T., Kingry, C., Ford, C., **Piller, L.**, et al. Operational Aspects of Terminating the Doxazosin Arm of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Controlled Clinical Trials* 2001;22: 29-41.
12. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Journal of the American Medical Association* 2000, 283:1967-1975.
13. Plehn, J., Davis, B., Sacks, F., Rouleau, J., Pfeffer, M., Bernstein, V., Cuddy, T., Moye, L., **Piller, L.**, et al. Reduction of Stroke Incidence After Myocardial Infarction with Pravastatin: The Cholesterol and Recurrent Events (CARE) Study. *Circulation* 1999, 99:216-223.

Articles submitted and under review by to peer-review journals, or currently in late stages and/or under internal review by writing group, ALLHAT Editorial Committee and/or NHLBI Project Office (all required before submission to journal):

14. Margolis, K., **Piller, L.**, Ford, C., et al. Blood Pressure Control in Hispanic ALLHAT Participants. Currently in final stages prior to submission.
15. Grimm, R., Davis, B., **Piller, L.**, et al. Heart Failure and Prior Blood Pressure Medication. In final stages.

16. Cutler, J., **Piller, L.**, Davis B., et al. Results of Monotherapy in ALLHAT: On-treatment Analysis. In late stages.
17. Alderman, M., **Piller, L.**, Davis, B., et al. The Clinical Significance of Incident Hypo- and Hyperkalemia in Treated Hypertensive Patients: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trials (ALLHAT). In final stages.
18. **Piller, L.**, Simpson, L., Habib, G. , Basile, J., et al. Major Secondary Events in ALLHAT: Angina, Revascularization, and Peripheral Artery Disease. In progress.
19. **Piller, L.**, Hanis, C., Fu, Yi-Ping, et al. Incidence and Prevalence of Diabetic Retinopathy Among Hispanics in Starr County. Texas. In progress.

ABSTRACTS AND PRESENTATIONS

1. G. Habib, J. Basile, D. Courtney, R. Dart, P. Einhorn, A. Ellsworth, H. Fendley, C. Furberg), F. Leenen, D. Morrison **L. Piller**, M Rahman, L. Simpson , P. Whelton . Are angiotensin converting enzyme inhibitors and/or calcium channel blockers superior to diuretics in preventing development of new or progressive angina or need for coronary or peripheral revascularization? Insights from the ALLHAT trial. Presented at the European Society of Hypertension Annual Meeting, June 12, 2006.
2. Alderman, M., **Piller, L.**, Ford, C., Davis, B., Einhorn, P., Cushman, W., Calhoun, D., Eckfeldt, J. The Relationship of Hypokalemia at 1 Year to Morbidity and Mortality: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Experience. Presented at the European Society of Cardiology Annual Meeting, September 7, 2005, Stockholm, Sweden.
3. **Piller, L.**, Ford, C., Davis, B, Nwachuku, C., Black, H., Oparil, S., Gappy, S., Retta, T., Probstfield, J. Angioedema in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *American Journal of Hypertension* 2005;18:92A. Presented at the American Society of Hypertension 20th Annual Scientific Meeting, held in San Francisco, CA, May, 2005.
4. Barry Davis, Richard Grimm, **Linda Piller**, Jeffrey Cutler, Karen Margolis, Joshua Barzilay, Richard Dart, James Graumlich, Robert Murden, Otelio Randall, and Katrina Sawyer, for the ALLHAT Collaborative Research Group. Use OF Case-Only Analysis In Clinical Trials - Rationale and Example. *Controlled Clinical Trials* 1995; 16(Supp 3):475. Presented at the Society of Clinical Trials, 16th Annual Meeting, May 5, 2005.
5. Einhorn, P., Davis, B., **Piller, L.**, Simpson, L., Kostis, J., Levy, D., Massie, B., Nwachuku, C., Black, H., Cushman, W. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure (HF) Validation Study: Clinical Presentation of Hospitalized HF Events and Subsequent Mortality Rates. *Circulation* 2004, Vol. 110, No. 17(S). Presented at the American Heart Association 2004 Annual Meeting, New Orleans, November, 2004.
6. Grimm, R., Davis, B., **Piller, L.**, Margolis, K., Barzilay, J., Dart, R., Graumlich, J., Murden, R., Randall, O., Sawyer, K. Did Type of Prior Antihypertensive Therapy Influence the Heart Failure Results in ALLHAT? *Journal of Hypertension* 2004;22(Suppl2);S151. Presented at the European Society of Hypertension (*ESH*) Fourteenth Annual Meeting, Paris, France, June, 2004.
7. Cutler, J., **Piller, L.**, Pressel, S., et al. Results of Monotherapy in ALLHAT: On-Treatment Analyses. *American Journal of Hypertension* 2004;17:S30-31. Presented at the American Society of Hypertension (*ASH*) Nineteenth Annual Scientific Meeting in New York City, New York, May, 2004; and at the European Society of Hypertension (*ESH*) Fourteenth Annual Meeting, Paris, France, June, 2004.
8. Einhorn, P., Davis, B., **Piller, L.**, deLeon, B, Simpson, L., Kostis, J., Levy, D., Massie, B., Nwachuku, C., Black, H., Cushman, W. Review of Heart Failure Events in The Antihypertensive and Lipid Lowering to Prevent Heart Attack Trial (ALLHAT): ALLHAT Heart Failure Validation Study. *Circulation* 2003;108:IV399-400. Presented at the American

Heart Association 2003 Annual Meeting, November, 2003.

9. **Piller, L.** Public Health Grand Rounds: ALLHAT Symposium, the University of Texas Health Science Center, School of Public Health, September 19, 2003.
10. DeLeon, B., **Piller, L.**, Simpson, L., Pressel, S., Bettencourt, J., Davis, B. Operational Aspects of the ALLHAT Heart Failure Validation Study. *Controlled Clinical Trials* 2003;24;186S. Presented at the Twenty-fourth Annual Meeting of the Society for Clinical Trials, London, England, July, 2003.
11. Davis, B., Ford, C., Pressel, S., Dunn, K., **Piller, L.** Sensitivity Analyses to Account for Losses to Follow-up in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Controlled Clinical Trials* 2003;24;76S. Presented at the Twenty-fourth Annual Meeting of the Society for Clinical Trials, London, England, July, 2003.
12. Ford, C., Margolis, K., **Piller, L.**, Cushman, W., Wright, J., Colon, P. Blood Pressure Control in Hispanics in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Presented at the Fifteenth Scientific Meeting of the Inter-American Society of Hypertension, San Antonio, TX, April, 2003.
13. **Piller, L.**, Simpson, L., Davis, B., et al. The Review of Event Reports in ALLHAT. *Controlled Clinical Trials* 2002;23;323. Presented at the Twenty-third Annual Meeting of the Society for Clinical Trials, Washington, D.C., May 12-15, 2002.
14. Simpson, L., Pressel, S., **Piller, L.**, Bettencourt, J., deLeon, B., Davis, B. Ascertainment of Vital Status Using Outside Databases in ALLHAT. *Controlled Clinical Trials*. 2002;23:76S. Presented at the Twenty-third Annual Meeting of the Society for Clinical Trials, Washington, D.C., May 12-15, 2002.
15. Davis, B., Pressel, S., Ford, C., **Piller, L.**, et al. The ALLHAT Clinical Trials Center—Expected and Unexpected Challenges. *Controlled Clinical Trials*. 2002; 23: 56S. Presented at the Twenty-third Annual Meeting of the Society for Clinical Trials, Washington, D.C., May 12-15, 2002.
16. Pressel, S., Davis, B., Ford, C., Bettencourt, J., deLeon, B., **Piller, L.**, et al. Closeout Procedures in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Controlled Clinical Trials*. 2002; 23: 57S. Presented at the Twenty-third Annual Meeting of the Society for Clinical Trials, Washington, D.C., May 12-15, 2002.
17. **Piller, L.**, Davis, B., Cutler, J., et. Al. Validation of Heart Failure Events in ALLHAT Participants Assigned to Doxazosin and Chlorthalidone. *American Journal of Hypertension*. 2001;14;180A. Presented at the American Society of Hypertension Sixteenth Scientific Meeting, San Francisco, CA, May, 2001.
18. Margolis, K., **Piller, L.**, Ford, C., et al. Blood Pressure Control in Hispanic Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Presented at the American Heart Association 41st Annual Conference on Cardiovascular Disease Epidemiology and Prevention, San Antonio, TX., April, 2001.
19. **Piller, L.**, Davis, B., Kimmel, B., et al. The Ascertainment of Endpoints by Primary Care Practitioners in a Long-Term Clinical Trial. *Controlled Clinical Trials*. 2000;21;104S. Presented at the Twenty-first Annual Meeting of the Society for Clinical Trials, Montreal, Canada, April 18, 2000.
20. Kimmel, B., Juratovac, A., Ragusa, P., **Piller, L.**, et al. Using Educational Grants to Improve Adherence and Retention in ALLHAT. *Controlled Clinical Trials*. 2000;21;105S. Presented at the Twenty-first Annual Meeting of the Society for Clinical Trials, Montreal, Canada, April 18, 2000.
21. Davis, B., Moye, L., **Piller, L.**, Simpson, L., Hawkins, M., Zimbalde, N. Reduction of Stroke Incidence After Myocardial Infarction with Pravastatin : The Cholesterol and Recurrent Events (CARE) Study. Presented at The University of Texas-Houston Health Science Center Research Day, October 8, 1999, and The University of Texas-Houston School of Public Health Faculty Research Day, November 12, 1999.

22. **Piller, L.,** Verani, R. Glomerulonephritis: A Case Study. Presented at the Texas Society of Pathologists Annual Meeting, San Antonio, Texas, 1989.

Other Publications and Presentations

1. Piller, LB. The Clinical Doctorate: A Boon to Pathologist. National Accrediting Agency for Clinical Laboratory Sciences (NAACLS) News 2006: 2;9
2. University of Texas Research Ethics Seminar: "Ethical Issues in Long-Term Clinical Trials." Presented at the University of Texas-Medical School, May 9, 2006
3. Public Health Grand Rounds, The University of Texas School of Public Health, Houston, Texas, September 19, 2003: ALLHAT Symposium
 - Plenary speaker: "Hypertension in the U.S."
 - Panel discussant
4. ALLHAT: From Beginning to End: Presented at Baylor College of Medicine/VA Internal Medicine Grand Rounds, (VA Medical Center), September 1-2, 2004.
5. ALLHAT: From Beginning to End: Presented at Baylor College of Medicine/VA Internal Medicine Grand Rounds, (VA Medical Center), March 31, 2004.
6. ALLHAT: From Beginning to End: Presented at Baylor College of Medicine/VA Internal Medicine Grand Rounds, (VA Medical Center), March 11, 2004.
7. ALLHAT: From Beginning to End Presented at Baylor College of Medicine/VA Internal Medicine Grand Rounds, (VA Medical Center), March 9, 2004.
8. ALLHAT 1998 Investigators' Meeting, Los Angeles, California
 - Discussion leader, Grand Rounds
9. ALLHAT 1999 Investigators' Meeting, Keystone, Colorado
 - Speaker, General Meeting, "Endpoints Ascertainment and Collection and Safety Reporting"
 - Discussion leader, Grand Rounds
 - Endpoints focus group co-leader, Steering Committee meeting
 - Endpoints discussion leader, Operations Subcommittee meeting
10. ALLHAT 2000 Investigators' Meeting, Orlando, Florida
 - Speaker, General Meeting, "Endpoints and Safety Reporting and Documentation"
 - Discussion leader, Grand Rounds